|Min SIP Amount||₹500|
|NAV||₹172.82 (16 Apr 2021)|
|Fund Started||07 Jan 2013|
|Fund Size||₹106 Cr|
|Stylam Industries Ltd.||FMCG||Equity||4.9%|
|Fortis Healthcare Ltd.||Healthcare||Equity||4.3%|
|Thyrocare Technologies Ltd.||Healthcare||Equity||4.1%|
|Tata Consultancy Services Ltd.||Technology||Equity||3.9%|
|Sun Pharmaceutical Inds. Ltd.||Healthcare||Equity||3.8%|
|JB Chemicals & Pharmaceuticals Ltd.||Healthcare||Equity||3.5%|
|Tech Mahindra Ltd.||Technology||Equity||3.5%|
|Bharti Airtel Ltd.||Communication||Equity||3.5%|
|Aurobindo Pharma Ltd.||Healthcare||Equity||3.3%|
Quant Tax Plan Direct Growth is a Equity Mutual Fund Scheme launched by Quant Mutual Fund. This scheme was made available to investors on 07 Jan 2013. Sanjeev Sharma, Shamil Mehra is the Current Fund Manager of Quant Tax Plan Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹106 Cr and the Latest NAV as of 16 Apr 2021 is ₹172.82.
The Quant Tax Plan Direct Growth is rated Very High risk. Minimum SIP Investment is set to 500. Minimum Lumpsum Investment is 500.
The scheme aims to generate capital appreciation by investing predominantly in equity shares with growth potential. The secondary objective is to give dividend and other income.
Upto Rs. 1.5 lac will be tax free under 80C. Lockin of 3 years. Returns will be taxed at 10%.